Medicare Enrolled
Dr. Nicholas Iannotti, MD, FACP
Hematology & Oncology · Port St Lucie, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Iannotti from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Iannotti? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Iannotti
Dr. Nicholas Iannotti is a hematology & oncology in Port St Lucie, FL, with 19 years in practice. Based on federal Medicare data, Dr. Iannotti performed 225,006 Medicare services across 8,033 unique beneficiaries.
Between the years covered by Open Payments, Dr. Iannotti received a total of $5,555 from 48 pharmaceutical and/or device companies across 232 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Iannotti is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 2% volume in FL$ $5,555 industry payments
Medicare Practice Summary
Medicare Utilization ↗225,006
Medicare services
Top 2% in FL for hematology & oncology
8,033
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,842 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | 64,440 | $0 | $2 |
| Filgrastim injection (Nivestym) for white blood cells | 32,820 | $0 | $2 |
| Iron infusion (Feraheme) | 28,050 | $0 | $3 |
| Pembrolizumab injection (Keytruda) | 17,400 | $43 | $91 |
| Denosumab injection (Prolia/Xgeva) | 15,480 | $19 | $30 |
| Paclitaxel chemotherapy injection | 13,440 | $0 | $2 |
| Epoetin alfa injection (Retacrit) for anemia | 4,880 | $6 | $24 |
| Epoetin alfa injection (Procrit) for anemia | 4,630 | $6 | $20 |
| Dexamethasone injection (steroid) | 4,324 | $0 | $1 |
| Contrast dye for imaging (iodine-based) | 4,250 | $0 | $1 |
| Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | 4,020 | $55 | $150 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,960 | $26 | $65 |
| Complete blood count (CBC) with differential | 3,531 | $8 | $30 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,240 | $24 | $94 |
| Blood draw (venipuncture) | 2,651 | $8 | $15 |
| Comprehensive metabolic blood panel | 2,092 | $10 | $30 |
| Office visit, established patient (20-29 min) | 2,001 | $70 | $210 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,590 | $1 | $10 |
| Carcinoembryonic antigen (cea) protein level | 874 | $19 | $55 |
| Drug injection, under skin or into muscle | 754 | $11 | $40 |
| Office visit, established patient (10-19 min) | 708 | $44 | $130 |
| Anti-nausea injection (ondansetron/Zofran) | 624 | $0 | $2 |
| Administration of chemotherapy into vein, 1 hour or less | 565 | $105 | $330 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 556 | $20 | $60 |
| Injection of additional new drug or substance into vein | 495 | $13 | $55 |
| Injection, carboplatin, 50 mg | 487 | $2 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 473 | $23 | $85 |
| Ferritin level test (iron stores) | 452 | $13 | $40 |
| Hospital follow-up visit, moderate complexity | 450 | $66 | $165 |
| Iron level test | 449 | $6 | $20 |
| Iron binding capacity test | 449 | $9 | $25 |
| Lactate dehydrogenase (enzyme) level | 345 | $6 | $20 |
| Injection, diphenhydramine hcl, up to 50 mg | 321 | $1 | $4 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 283 | $58 | $125 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 254 | $51 | $150 |
| Vitamin B-12 level test | 252 | $15 | $50 |
| Folic acid level test | 250 | $14 | $55 |
| Administration of chemotherapy into vein, each additional hour | 190 | $23 | $80 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 176 | $27 | $85 |
| Administration of additional new drug or substance into vein, 1 hour or less | 174 | $53 | $165 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 166 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 163 | $16 | $50 |
| PSA test (prostate cancer screening) | 147 | $18 | $75 |
| Infusion, normal saline solution , 1000 cc | 144 | $2 | $10 |
| Initial hospital admission, high complexity | 142 | $143 | $460 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 140 | $4 | $12 |
| Infusion into a vein for hydration, each additional hour | 131 | $10 | $40 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 123 | $397 | $681 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 115 | $136 | $437 |
| Irrigation of implanted venous access drug delivery device | 114 | $18 | $55 |
| Prothrombin time test (blood clotting) | 113 | $4 | $15 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 112 | $1,175 | $5,700 |
| New patient office visit (45-59 min) | 110 | $123 | $390 |
| Infusion into a vein for hydration, 31-60 minutes | 105 | $26 | $125 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 102 | $3 | $10 |
| Magnesium level test | 86 | $7 | $20 |
| Manual urinalysis test with examination using microscope, non-automated | 84 | $4 | $20 |
| New patient office visit, complex (60-74 min) | 81 | $176 | $520 |
| Collection of blood sample from implanted device | 67 | $21 | $50 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 55 | $1 | $4 |
| Stool analysis for blood, by peroxidase activity | 50 | $4 | $10 |
| Office visit, established patient (30-39 min) | 45 | $100 | $300 |
| Drawing of blood for a medical problem | 42 | $73 | $165 |
| Blood creatinine level | 35 | $5 | $15 |
| Urea nitrogen level to assess kidney function, quantitative | 35 | $4 | $7 |
| Ct scan of chest with contrast | 31 | $66 | $700 |
| Basic metabolic blood panel | 28 | $6 | $25 |
| Ct scan of abdomen and pelvis without contrast | 22 | $84 | $1,075 |
| Ct scan of abdomen and pelvis before and after contrast | 21 | $221 | $1,450 |
| CT scan of chest, without contrast | 17 | $36 | $319 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
13.1% high complexity
79.5% medium
7.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,555
Total received (2018-2024)
Avg $794/year across 7 years
Top 47% in FL for hematology & oncology
48
Companies
232
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,345 (96.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$210 (3.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$487
2023$405
2022$109
2021$261
2020$345
2019$554
2018$3,394
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$533
Genentech USA, Inc.
$481
Takeda Pharmaceuticals U.S.A., Inc.
$467
Amgen Inc.
$458
Lilly USA, LLC
$371
AstraZeneca Pharmaceuticals LP
$347
Janssen Biotech, Inc.
$308
Novartis Pharmaceuticals Corporation
$296
Tempus AI, Inc
$233
TESARO, Inc.
$163
Kite Pharma, Inc.
$163
Bayer HealthCare Pharmaceuticals Inc.
$146
Seattle Genetics, Inc.
$145
Incyte Corporation
$126
Janssen Scientific Affairs, LLC
$108
United Therapeutics Corporation
$100
Gilead Sciences, Inc.
$98
E.R. Squibb & Sons, L.L.C.
$91
Merck Sharp & Dohme Corporation
$89
ABBVIE INC.
$88
MEDIVATION FIELD SOLUTIONS LLC
$71
Astellas Pharma US Inc
$65
Ipsen Biopharmaceuticals, Inc
$52
Daiichi Sankyo Inc.
$50
Celgene Corporation
$46
Pharmacyclics LLC, An AbbVie Company
$46
AbbVie Inc.
$37
Boehringer Ingelheim Pharmaceuticals, Inc.
$36
Alexion Pharmaceuticals, Inc.
$34
Aurobindo Pharma USA, Inc.
$29
EISAI INC.
$23
Karyopharm Therapeutics Inc.
$22
Merck Sharp & Dohme LLC
$22
Shire North American Group Inc
$19
SOBI, INC
$19
GlaxoSmithKline, LLC.
$17
Puma Biotechnology, Inc.
$16
AbbVie, Inc.
$15
R-Pharm US LLC
$14
INSYS Therapeutics Inc
$14
TOLMAR Pharmaceuticals, Inc.
$14
GENZYME CORPORATION
$14
Eisai Inc.
$13
Agios Pharmaceuticals, Inc.
$12
AMAG Pharmaceuticals, Inc.
$12
Otsuka America Pharmaceutical, Inc.
$11
Seagen Inc.
$11
JAZZ PHARMACEUTICALS INC.
$11
Top 3 companies account for 26.7% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · Abraxane · Alecensa · Avastin · BLENREP · BOSULIF · CYRAMZA · DARZALEX · Doptelet · ELIGARD · ELIQUIS · ELITEK · ERBITUX · FERAHEME · Folotyn · Fusilev · GAZYVA · GILOTRIF · Herceptin · IBRANCE · ICLUSIG · IDHIFA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · Imbruvica · Ixempra · JAKAFI · KEYTRUDA · KISQALI · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NINLARO · Nerlynx · Neulasta · Nplate · OPDIVO · PADCEV · PLUVICTO · PROMACTA · Perjeta · REBLOZYL · Revlimid · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TALVEY · TASIGNA · TECENTRIQ · TECVAYLI · UNITUXIN · VENCLEXTA · VERZENIO · VOTRIENT · VPRIV · Vectibix · Venclexta · XALKORI · XGEVA · XPOVIO · XT CDX · XTANDI · Xofigo · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
24
Per 100K population
6.9
County median income
$69,027
Nearest hospital
ST LUCIE MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Iannotti is a mixed practice specialist, with above-average Medicare volume (top 2% in FL), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Iannotti experienced with injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram?
Based on Medicare claims data, Dr. Iannotti performed 64,440 injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Iannotti receive payments from pharmaceutical companies?
Yes. Dr. Iannotti received a total of $5,555 from 48 companies across 232 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Iannotti's costs compare to other hematology & oncologys in Port St Lucie?
Dr. Iannotti's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Iannotti) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Port St Lucie
Browse hematology & oncologys in Port St Lucie ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc..
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology